Genetic variants help uncover potential new treatment pathway in kidney cancer
Investigators have found that inhibition of the purine salvage pathway in hereditary leiomyomatosis and renal cell ...
Author Archive
Malcolm Packer
Malcolm is Chief Executive Officer at Kidney Cancer UK and Kidney Cancer Scotland and has worked with the charity in various capacities for over 15 years.
National Cancer Research Institute (NCRI) to close
The National Cancer Research Institute (NCRI) has announced that it will be winding down its operations prior to ...
New Nephrectomy Support Fact Sheets
Kidney Cancer UK is delighted to announce that collaboration with senior NHS clinicians has resulted in the ...
TKI/Immunotherapy & side effect management Webinar – Watch Again
Online Support Groups
Join us and other kidney cancer patients for a online get together.
Webinar – TKI/Immunotherapy and side effect management
Patient’s tumour removed in world-first histotripsy treatment at Leeds Cancer Centre
A cancer patient from West Yorkshire has become the first person in the world to have a kidney tumour removed ...
ALLO-316 Demonstrates Antitumor Activity in Advanced ccRCC
Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma ...
Belzutifan+cabozantinib shows promise for advanced RCC, study shows
belzutifan+cabozantinib combination therapy show promise as an option for advanced kidney cancer patients already ...
Is there mushroom for debate?
It seems that many people touched by cancer are turning to the Turkey Tail Mushroom trend, the extract from which ...
TKI Treatment Breaks May Not Impact Outcomes in RCC
Patients with advanced clear cell renal cell carcinoma are “unlikely” to experience a clinically meaningful ...
Kisplyx -Keytruda Continues to Show Benefit in Advanced Kidney Cancer
The drug duo Kisplyx plus Keytruda led to improved outcomes for patients with advanced renal cell carcinoma, ...
No results found.